1. Home
  2. TPG vs CYTK Comparison

TPG vs CYTK Comparison

Compare TPG & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TPG Inc.

TPG

TPG Inc.

HOLD

Current Price

$65.16

Market Cap

8.9B

Sector

Finance

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$63.06

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPG
CYTK
Founded
1992
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9B
8.0B
IPO Year
2022
2004

Fundamental Metrics

Financial Performance
Metric
TPG
CYTK
Price
$65.16
$63.06
Analyst Decision
Buy
Strong Buy
Analyst Count
12
16
Target Price
$66.45
$82.38
AVG Volume (30 Days)
1.3M
2.2M
Earning Date
02-09-2026
02-26-2026
Dividend Yield
2.63%
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$4,255,344,000.00
$87,211,000.00
Revenue This Year
N/A
$346.43
Revenue Next Year
$31.12
$57.69
P/E Ratio
$677.41
N/A
Revenue Growth
24.91
2609.26
52 Week Low
$37.52
$29.31
52 Week High
$70.38
$70.98

Technical Indicators

Market Signals
Indicator
TPG
CYTK
Relative Strength Index (RSI) 51.90 50.68
Support Level $65.11 $60.30
Resistance Level $67.50 $65.25
Average True Range (ATR) 1.70 2.84
MACD -0.31 0.11
Stochastic Oscillator 21.40 60.08

Price Performance

Historical Comparison
TPG
CYTK

About TPG TPG Inc.

TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: